FDA Approval Process for PAH Drugs The past decade has seen many new drugs approved to treat PAH. The development of a new drug is a long and expensive process. Candidate new drugs are identified and then enter the clinical research pathway. Before a medication is ever tested in humans, the medication is tested in a variety of laboratory settings and then in animal models. … [Read more...]
Pulmonary Arterial Hypertension Life Expectancy & Survival Rates
The treatment for Pulmonary Arterial Hypertension has come a long way since the mid 1990’s when Flolan was first approved. There has been an explosion of new medications that have dramatically altered how we treat patients. We no longer sequentially add therapies to most of our patients. Rather, we often start two or even three different therapies as part of an initial … [Read more...]
Help Arrives for Some PAH Patients Who Can’t Afford Their Medication
Thousands of Pulmonary Arterial Hypertension patients across America are now experiencing a crisis. They previously received support from Caring Voices Coalition. With the closing of Caring Voices, many of these patients have been unable to find foundation support, leaving them responsible for many thousands of dollars per month to receive their PAH medications. The PHA and … [Read more...]
Update on the Implantable System for Remodulin
On December 22, 2017, after eight years of study, the FDA has finally granted pre-market approval (PMA) to the fully implantable system for Remodulin. This groundbreaking pump and catheter system allows patients to benefit from Remodulin while minimizing the inconvenience and risks associated with having an external intravenous catheter. However, this does not mean that the … [Read more...]
Financial Assistance for Pulmonary Hypertension Patients with Medicare, Medicaid & Military Benefits
Assistance Now Available. Where to get financial assistance for the very expensive drugs used to treat Pulmonary Arterial Hypertension remains a hot topic. With an average treatment cost of around $100,000 per PAH patient per year, financial assistance is in great demand. Pulmonary Hypertension patients that are uninsured or privately insured have options for financial … [Read more...]
